IDSA '98 highlights.
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006297:Health Services Accessibility; D006561:Herpes Simplex / Q000150:complications; D006566:Herpesviridae Infections / Q000150:complications / Q000453:epidemiology; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000209:etiology*; D012367:RNA, Viral / Q000097:blood; D013577:Syndrome; D014456:Ulcer / Q000150:complications; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral